This review highlights endogenous cardiac stem cell therapy as a promising autologous strategy for treating ischemic heart failure, while noting the mixed results and safety concerns of other stem cell types.
No takes yet. Share an insight, caveat, or question.
Endogenous cardiac stem cells merit targeted trials in ischemic HF; leaves open comparative efficacy and safety of other approaches.
Lien‐Cheng Hsiao (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: